❌ HB276
Prohibit certain actions re: reimbursing 340B covered entities
Current Status: In House Committee (Insurance)
Summary
HB276 prohibits drug manufacturers, repackagers, and third-party logistics providers from denying or restricting the acquisition and delivery of 340B drugs to 340B grantees. It also prevents these entities from requiring claims or utilization data as a condition for such acquisitions or deliveries, with penalties for violations including civil fines and potential referral to the state board of pharmacy.
Rationale
The bill imposes restrictions on drug manufacturers and may increase government control over the pharmaceutical market, conflicting with the Libertarian principles of free markets and minimal government intervention.
Risks and Concerns
- Increased government control over pharmaceutical practices
- Potential for cronyism in the healthcare sector
- Limits on free market competition